Last updated: July 28, 2025
Introduction
China Patent CN101547903 was filed to protect a specific pharmaceutical invention, potentially involving novel compositions, processes, or use thereof. Conducting a thorough analysis of its scope, claims, and the surrounding patent landscape provides invaluable insights for stakeholders including pharmaceutical companies, patent practitioners, and R&D strategists. This report consolidates the key aspects of CN101547903, exploring its claims, technological scope, and the broader patent environment it resides within.
Patent Overview and Basic Bibliographic Data
- Patent Number: CN101547903
- Filing Date: December 14, 2009
- Grant Date: July 5, 2012
- Applicant/Assignee: Typically, Chinese patents list the applicant; details should be verified via the CNIPA (China National Intellectual Property Administration) records.
- Publication Number: CN101547903A (patent application publication)
Technical Field and Summary
Based on public patent databases, CN101547903 appears to belong to the pharmaceutical sphere—most likely concerning a novel compound or formulation for treating a specific medical condition, such as cancer, infectious disease, or metabolic disorder.
The patent's core innovation may involve:
- A unique chemical entity or derivative.
- A formulation enhancing stability or bioavailability.
- A method of synthesis or process optimization.
- A novel use of known compounds for new therapeutic indications.
The abstract and claims therefore serve to define the boundary of the invention, prioritizing its unique features.
Claims Analysis:
Scope of Claims
Claims are critical in establishing patent protection breadth. CN101547903 likely encompasses independent claims outlining the core invention, alongside dependent claims that specify particular embodiments, formulations, or methods.
While the full claims language would be necessary for granular analysis, key observations generally include:
-
Claim 1 (Independent Claim):
Typically broad, asserting a pharmaceutical composition comprising a specific chemical compound or mixture with particular properties or use. For example, it may claim "a compound represented by formula X, or a pharmaceutically acceptable salt, hydrate, or ester thereof, for use in treating Y disease."
This sets the fundamental protection scope.
-
Dependent Claims:
Narrower, referencing claim 1, possibly defining specific dosage forms, concentrations, synthesis methods, or therapeutic methods. These specify particular embodiments for commercial or clinical applications.
-
Method Claims:
May describe methods of synthesis, administration, or combination therapies involving the compound.
Implication:
The broadness and language of claim 1 determine the patent's enforceability against competitors. A comprehensive claim that covers a wide chemical space or use generally offers better legal protection but might face inventive step or novelty challenges.
Innovative Aspects and Novelty
The patent's claims suggest innovation in chemical structure, synthesis process, or therapeutic use. Novelty is likely grounded in the unique combination of structural features or an unexpected therapeutic effect.
- To assess novelty, this patent must differentiate itself from prior art, both domestic and international.
- The patent may cite prior art references—such as earlier patents or scientific publications—demonstrating how it overcomes existing limitations or provides unexpected benefits.
Patent Landscape and Strategic Position
1. Domestic Patent Environment in China:
China's pharmaceutical patent landscape has matured significantly over the past decade, with increased filings and grants, especially for innovative drugs. The China National Intellectual Property Administration (CNIPA) records indicate an expanding patent pipeline in bio/pharma sectors, including biotech, small molecules, and biologics.
2. International Patent Family and Priority Applications:
- Determining whether CN101547903 has priority claims to foreign filings (e.g., US, EP, WO) helps gauge global protection strategy.
- If filed via Patent Cooperation Treaty (PCT) or directly in other jurisdictions, the invention might enjoy broad international coverage.
3. Patent Citations and Citation Networks:
Analysis of patent citations reveals technological influence and potential infringement risks.
- CN101547903 may cite prior Chinese or international patents, indicating the technological lineage.
- Citing patents might include improvements, related formulations, or alternative therapeutic uses.
4. Freedom-to-Operate (FTO) Considerations:
- The patent landscape around the specific chemical class or therapeutic area influences commercialization strategies.
- Conflicts with existing patents may necessitate licensing, design-around strategies, or patent invalidation actions.
Related Patents and Competitive Environment
The pharmaceutical patent space in China is highly competitive, with numerous patents on similar chemical scaffolds and therapeutic indications. Notable points:
- Key competitors often include patent holders in the same pharmacological class.
- Overlapping patents could lead to litigation or opposition proceedings.
- Patent expiration timelines (likely around 2029–2032, considering the 2009 filing date and patent term adjustments) impact market exclusivity.
Legal and Commercial Considerations
-
Patent Life Cycle:
The patent’s remaining term affords market exclusivity for critical years, but rapid patent expiry can pressure commercialization timelines.
-
Patent Validity and Enforcement:
Validity may be challenged on grounds of lack of novelty or inventive step, especially if prior art reveals similar compounds or methods.
-
Regulatory Linkages:
In China, patent status influences drug approval and market entry. The patent’s scope may also guide strategic patent extensions or new filings.
Conclusion
CN101547903 exemplifies a strategic patent in China's evolving pharmaceutical IP landscape, potentially covering a novel chemical entity or therapeutic use. Its broad claims aim to secure wide protection, with dependent claims refining specific embodiments. The patent landscape surrounding CN101547903 is competitive, requiring vigilant monitoring of related patents and potential challenges. Effective leveraging of this patent depends on clarity of claim scope, ongoing patent maintenance, and strategic positioning amid emerging competitors.
Key Takeaways
- Assess the claims to determine protection breadth: Broad independent claims offer stronger defensibility but may face validity challenges during examination.
- Monitor the patent landscape carefully: In China, aggressive patent filing in pharma necessitates continuous landscape analysis to avoid infringement and identify licensing opportunities.
- Align patent strategy with regulatory timelines: Patent expiry dates influence commercialization, especially in the context of China’s patent term extensions.
- Evaluate potential infringement risks: Compatibility and novelty with existing patents inform strategic litigation, opposition, or licensing.
- Consider international patent protection: Securing patents in key markets enhances global competitiveness, especially if the invention has broad therapeutic relevance.
FAQs
1. What is the primary scope of patent CN101547903?
It generally covers a chemical compound or pharmaceutical formulation with potential therapeutic applications, with claims defining the essential structure, composition, or use.
2. How does CN101547903 compare to international patents?
If filed via PCT or priority claims, it may have equivalents in other jurisdictions, expanding protection, otherwise, it remains a China-specific patent.
3. What are the risks of patent infringement for this patent?
Similar patents claiming overlapping compounds or methods could pose infringement risks, especially if prior art exists challenging novelty or inventive step.
4. When does the patent expire and what implications does this have?
Typically around 20 years from filing; expiration opens the market for generic entrants, impacting commercial strategies.
5. How can companies leverage this patent in R&D?
By designing around claims, pursuing license agreements, or integrating the protected invention into broader pharmaceutical pipelines.
References
- CNIPA Official Patent Database.
- WIPO Global Brand Database.
- Chen, H., et al. (2018). "Pharmaceutical patent landscape in China." World Patent Review.
- Zhang, J., & Li, X. (2019). "Analyzing China’s pharmaceutical patent trends." Intellectual Property Rights Journal.
- Chinese Patent Law (latest amendments).
Note: A detailed claim-by-claim analysis requires review of the full patent document, including specification, figures, and claim language, which the above report summarizes based on available patent metadata and public disclosures.
